vTv Therapeutics has secured an $80 million PIPE to fund the ongoing CATT1 phase 3 trial and continued development of cadisegliatin, a liver-selective glucokinase activator being studied as the first oral adjunct to insulin for type 1 diabetes. The round, expected to close around September 3, 2025, combines common stock, pre-funded warrants, and accompanying warrants and includes participation from existing backers and new investors alongside the T1D Fund. The company guides topline data in the second half of 2026, with the phase 3 program evaluating reductions in Level 2 and 3 hypoglycemic events and improvements in glycemic control.
The financing signals that late-stage capital will still move for assets addressing clear clinical friction points—here, hypoglycemia risk and day-to-day burden in a population where insulin remains the only approved cornerstone and prior adjuncts have stumbled. The inclusion of disease-focused capital from the T1D Fund underscores a thesis that the combination of strong mechanistic rationale, Breakthrough Therapy designation, and outcome-relevant endpoints can overcome historic skepticism that has shadowed adjunctive therapies in type 1 diabetes. The warrant-heavy structure and exercise prices suggest investors are underwriting binary clinical risk while leaving room for upside if the class finally finds traction in T1D.
For patients and HCPs, the stakes are practical: severe hypoglycemia drives emergency visits, erodes quality of life, and complicates the adoption of intensive insulin therapy even in an era of CGMs and automated insulin delivery. If cadisegliatin can demonstrate meaningful reductions in serious hypoglycemic events without increasing diabetic ketoacidosis, it could be the first pharmacologic complement to insulin to gain real-world traction in T1D since pramlintide, which struggled with adherence and workflow. For payers, the economic signal will need to be explicit—fewer ER admissions, fewer hospitalizations, and CGM-derived improvements in time-in-range—framed within a price that aligns with chronic oral therapy in a narrow specialty segment rather than the premium obesity/diabetes market.
Competitively, a positive readout would open a new lane distinct from GLP-1s and SGLT inhibitors, the latter having faced regulatory headwinds in T1D due to DKA risk in the U.S. A liver-selective glucokinase activator aims to leverage hepatic glucose uptake and glycogen storage to smooth glycemic variability, a mechanism that could integrate with insulin pumps and closed-loop systems rather than compete with them. That alignment with device-driven care is strategically important: formularies and guidelines increasingly emphasize integrated outcomes, and Medical Affairs will need to generate prospective and real-world evidence linking cadisegliatin use to reductions in severe hypoglycemia verified by CGM event definitions, alongside neutral signals on ketones, lipids, and liver enzymes.
The deal also illustrates a broader trend in biotech financing: selective PIPEs backing late-stage, single-asset stories where a near-term catalyst can reset valuation. Disease-focused venture participation continues to shape development priorities, accelerating programs that can demonstrate payer-relevant endpoints and pragmatic prescribing pathways in specialty care. For vTv, this capital likely funds not just the completion of CATT1 but also pre-commercial evidence generation, health economic modeling, and HCP education geared to endocrinology practices.
With topline data targeted for the second half of 2026, the next strategic question is whether cadisegliatin can deliver a clinically convincing and regulatorily acceptable benefit on severe hypoglycemia without safety trade-offs—and if so, how quickly the field can translate that into guideline inclusion, integrated pump/CGM workflows, and a value story that payers are prepared to reimburse at scale.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
